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The humoral and cell-mediated immune responses to subsequent allografts 
were determined in primate recipients after concordant xenotransplanta- 
tion as a bridge to allotransplantation. Heterotopic heart transplants (n = 
4) were performed from cynomolgus monkeys into ABH type-matched olive 
baboons followed 2 weeks later by allotransplantation from ABH type- 
matched baboon donors. Allografts were explanted at 8 weeks. All re- 
cipients underwent splenectomy at the time of xenotransplantation and 
received immunosuppression with cyclosporine, azathioprine, and methyl- 
prednisolone. Concordant xenotransplantation i these primates did not 
induce humoral or cell-mediated immune responses that jeopardized 
subsequent allografts. The degree of xenospecific immune reactivity, as 
determined by specific ytotoxicity of recipient T-cell lines derived from the 
xenograft and extent of histologic xenograft rejection, did not predict the 
severity of subsequent aUograft rejection. In two of the four recipients, 
xenotransplantation i duced an alloreactive humoral response against anti- 
gens expressed by the B cells of more than 50% of members from a panel of 12 
unrelated baboons. In all recipients, priming with xenogeneic splenocytes in 
vitro induced an accelerated proliferative T-cell response to allogeneic lym- 
phocytes from 16% of this panel. This study affirms the role of concordant 
xenografts as appropriate biologic bridges to human allotransplantation. 
However, our results suggest that xenoreactive baboon memory CD4 T cells 
may recognize major histocompatibility complex class II-like structures 
shared between the xenogeneic and allogeneic targets. The potential allorecog- 
nition induced by a xenograft may affect the process of subsequent allograft 
donor selection. (J Thorac Cardiovasc Surg 1996;112:1002-9) 
A lthough clinical heart transplantation with hu- man cadaveric donors is recognized as the most 
effective therapy for patients with end-stage heart 
disease, the supply of human donor hearts remains 
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inadequate to meet the ever-increasing demand. 1-3 
The experimental search for an alternative to hu- 
man heart transplantation has focused primarily on 
two alternatives: mechanical devices and cross-spe- 
cies transplants (xenografts). For children and 
adults with a total body surface area less than 1.5 m 2, 
in whom mechanical devices are not applicable, 
xenografts may be the preferred alternative. 4 
The field of clinical cross-species transplanta- 
tion was pioneered by Reemtsma nd colleagues 5 
in 1963. Reemtsma transplanted chimpanzee kid- 
neys into human beings and achieved functional 
graft survival for up to 9 months with the use of 
azathioprine and steroid based immunosuppression. 
Although initial attempts at clinical heart xenotrans- 
plantation were largely unsuccessful, experimental 
studies during the past decade have demonstrated 
the feasibility and potential benefit of cross-species 
heart transplantation. 912 
Although much excitement has been generated by 
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the development of transgenic pigs, it is unlikely that 
these animals will be ready for clinical trials within 
the next 5 years. Moreover, colony-bred baboons 
may be available in sufficient numbers to meet the 
pediatric demand for hearts. 13 
Rejection of a concordant xenograft is character- 
ized histologically by mononuclear nd polymorpho- 
nuclear cellular infiltrates accompanied by intersti- 
tial edema and eventually hemorrhage, vascular 
thrombosis, and myocyte necrosis. 1° These features 
result from immunologic effector mechanisms in- 
volving both humoral and cellular responses to 
concordant xenografts. 9' 14-19 These findings raise 
the question of whether a concordant xenograft 
implanted as a temporary bridge to allotransplanta- 
tion could induce a humoral or cell-mediated im- 
mune response that is capable of jeopardizing a 
subsequent allograft. The issue of sensitization to 
subsequent allografts induced by concordant xeno- 
transplantation has been investigated in rodent and 
canine animal models but has not been well studied 
in primates, z°-z3 Findings in smaller animal models 
have been equivocal. In a hamster-to-rat hetero- 
topic heart transplant model, there was no differ- 
ence in untreated allograft survival after xenotrans- 
plantation. 21 In contrast, survival of canine 
allografts in a wolf-to-dog heterotopic heart trans- 
plant model was found to be decreased after con- 
cordant xenotransplantation, with five of nine allo- 
grafts undergoing "hyperacute" rejection within 48 
hours of implantation, z° The mechanism of the 
rejection response was presumed to be humoral, this 
presumption being based primarily on histopatho- 
logic findings. The antibody response of the recipi- 
ents to their xenografts was monitored only by 
hemagglutination f xenograft donor erythrocytes, 
and this response did not correlate with allograft 
rejection. The applicabilit7 of data from small ani- 
mal studies to the human condition is questionable 
inasmuch as the identity of relevant xenoantigens in 
these species have not been clearly established. 
The purpose of this study, therefore, was to 
determine how a concordant primate xenograft in- 
fluences the rejection of a subsequent allograft. A 
cynomotgus monkey-to-ol ive baboon heart trans- 
plant model was selected because the degree of 
immunologic disparity between these species is be- 
lieved to closely parallel that between human beings 
and higher primates and may uniquely reflect rejec- 
tion reactions expected between human beings and 
baboons. 24 
Materials and methods 
Animals. Concordant heterotopic heart xenotrans- 
plants were performed using cynomolgus monkey (Ma- 
caca fascicularis) donors into ABH type-matched olive 
baboons (Papio anubis; n = 4). The xenografts were 
explanted after 2 weeks, followed by allotransplantation 
from ABH type-matched olive baboon donors. Allografts 
were explanted after 8 weeks. ABH compatibility was 
determined by salivary analysisY' 26 
Surgical procedures and subsequent care of animals 
were performed in compliance with the Principles of 
Laboratory Animal Care formulated by the National 
Society- for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Na- 
tional Academy of Sciences and published by the National 
Institutes of Health (NIH publication No. 85-23, revised 
1985). 
Heterotopie cervical heart transplantation. Donor 
heart procurement, graft preparation, and recipient cer- 
vical implantation were performed as previously described 
by Michler and associates. 27In brief, donor hearts were 
procured in a fashion similar to the manner in which 
human hearts are harvested for allotransplantation, with 
University of Wisconsin preservation solution (15 ml/kg, 
4 ° C, infusion pressure 50 to 100 mm Hg). The grafts 
were implanted into the baboon recipients in the cervi- 
cal position by performing end-to-side anastomoses 
with continuous polypropylene suture first between the 
donor aorta and recipient carotid artery and second 
between the donor pulmonary artery and recipient jugu- 
lar vein. All recipients underwent splenectomy at the time 
of xenotransplantation. The total number of animals 
undergoing this procedure was four and survival was 
100%. 
Heterotopic allotransplantation in baboon recipients 
was performed in the contralateral side of the neck at the 
time of xenograft explantation. All recipients received 
cyclosporine (15 mg/kg per day), azathioprine (3 mg/kg 
per day), and methylprednisolone (0.8 mg/kg per day) 
immunosuppression from the time of xenotransplanta- 
tion. Biopsy specimens for light and immunofluorescence 
microscopy were obtained from the xenograft 1 and 2 
weeks after transplantation a d from the allograft 1, 4, 
and 8 weeks after transplantation. Rejection episodes 
were not treated. 
Histology/immnnopathology. Samples of graft tissue 
for immunohistochemical evaluation were snap frozen 
in prechilled isopentane and liquid nitrogen and stored 
at -70 ° C. As described previously, specimens were cut 
into 4 ~m sections in a cryostat (Leica Vertrieb GmbH, 
Bensheim, Germany) at -25 ° C, air dried, fixed in 
acetone for 10 minutes, and washed with phosphate- 
buffered saline solution (pH 7.4). 28 Each section was 
then incubated with either an affinity-isolated, fluores- 
cein isothiocyanate (FITC)-conjugated, labeled pri- 
mary antibody or with an unlabeled murine monoclonal 
antibody (MAb). FITC goat antihuman immunoglobu- 
1ins (Ig) G and M were obtained from Kirkegaard & 
Perry Laboratories (Gaithersburg, Md.). FITC goat 
antihuman C3 was obtained from Cappel Laboratories 
(Organon Teknika Corp., Durham, N.C.). FITC goat 
1 0 0 4 Michler et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1996 
antihuman C4 and FITC rabbit antihuman fibrin were 
obtained from Accurate Chemical & Scientific Corp. 
(Westbury, N.Y.). A murine MAb against the mem- 
brane attack complex (MBM5) was generously provided 
by Alfred Michael (University of Minnesota, Minneap- 
olis, Minn.). Mouse antihuman CDll/CD18 (OKM1) 
was obtained from Ortho Pharmaceutical Corporation 
(Raritan, N.J.), and mouse antihuman CD9 (BA-2) was 
the gift of T. W. LeBien (University of Minnesota). The 
unlabeled MAbs were detected with affinity-isolated 
FITC F(ab')2 goat antimouse IgG (Cappel) followed by 
affinity-isolated FITC F(ab')2 rabbit antigoat IgG (Cap- 
pel). Before use, the secondary antibodies were ab- 
sorbed with pig and human serum. Sections were 
washed with phosphate-buffered saline solution and 
mounted in a solution containingp-phenylenefiamine. 29 
In all experiments, control sections were stained as 
described herein; however, the primary antibodies were 
omitted. 
Biopsy specimens from the grafts for histologic study 
were fixed in formalin, embedded in paraffin, sectioned, 
and stained with hematoxylin and eosin. Rejection was 
graded 0 to 4 according to the standardized criteria 
described by Billingham and colleagues 3°in 1990. 
Immunologic assays 
Studies of immune reactivity in vivo to allogeneic targets 
after xenotransplantation. Recipients were studied for the 
presence of humoral and cell-mediated reactivity to spe- 
cific and unrelated allogeneic donors before and after 
exposure to the xenograft in vivo. Sera were obtained 
from each recipient for immunologic assays before xeno- 
transplantation a d then twice weekly until allograft ex- 
plantation. 
COMPLEMENT-MEDIATED LYMPHOCYTOTOXICITY. Com- 
plement binding antilymphocyte antibodies in recipient 
sera directed against T and B lymphocytes of the 
specific allograft donor and a panel of unrelated ba- 
boon donors (n = 12) were detected by the standard 
microlymphocytotoxicity technique. Rabbit comple- 
ment was absorbed on donor lymphocytes before the 
cells were added to recipient sera. All testings were 
done in parallel on purified T- and B-lymphocyte 
suspensions to detect antibodies directed against major 
histocompatibility complex (MHC) class I and class II 
antigens. Sera were tested before and after reduction of 
IgM with dithiothreitol to discriminate between IgM 
and IgG lymphocytotoxic antibodies. 31
PROLIFERATIVE STUDIES. To analyze the potential allo- 
reactivity of recipient T cells infiltrating the xenograft, we 
explanted graft biopsy specimens in medium supple- 
mented with recombinant interleukin-2 (5 units/ml), and 
irradiated autologous peripheral blood mononuclear cells. 
T-cell lines were propagated for 10 to 14 days. Recipient 
T-cell lines derived from the biopsy specimens were then 
cultured with irradiated lymphocytes from the xenogeneic 
and allogeneic donors for 3 days. Over the last 18 hours of 
culture, the cells were incubated with thymidine labeled 
with tritium (3H-TdR) (1 /xCi/ml). Cultures were har- 
vested and the amount of 3H-TdR incorporation was 
measured in an LK Betaplate liquid scintillation counter 
(Wallac, Inc., Gaithersburg, Md.). 
CYTOTOXICITY ASSAYS. To determine whether the pop- 
ulation of T cells infiltrating the xenograft was composed 
of xenoreactive and alloreactive cytotoxic T lymphocytes, 
T-cell lines derived from the xenograft biopsy tissue were 
tested for specific cytotoxicity against xenogeneic and 
allogeneic targets. Lymphocytes (106/ml) from the specific 
xenograft and allograft donor were stimulated with 2 t~g 
phytohemagglutinin (Sigma Chemical Co., St. Louis, Mo.) 
for 3 days in culture medium (RPMI 1640 medium 
[Roswell Park Memorial Institute, Buffalo, N.Y.] with 
10% fetal calf serum, glutamine, and gentamicin). The 
lymphocytes were then collected, washed in culture me- 
dium, and labeled at 37°C for 1 hour with 51Cr (0.1 
mCi/ml) for use as targets. 
Target cells (10 4 ) were plated in 96 u-bottom plates in 
a total volume of 0.1 ml. Effector T cells were plated at 
5 × 104/well in 0.1 ml medium. After 4 hours the plates 
were centrifuged and 0.1 ml supernatant from each well 
was collected for measuring 51Cr release in a gamma 
counter (United Technologies Packard, Downers Grove, 
Ill.). For determination of spontaneous and maximum 
release, 0.1 ml medium or 0.2% Triton 100 (Union 
Carbide Corp., Danbury, Conn.) was added to target cells. 
Specific lysis was determined by the formula: 100 × 
(Experimental-spontaneous release/Maximum-spontane- 
ous release). 
Studies of immune reactivity to allogeneic targets after 
priming with xenogeneic cells in vitro. To determine 
whether T cells primed by MHC class II-like antigens 
expressed on xenogeneic donor cells displayed accelerated 
memory responses against allogeneic targets, we per- 
formed the following experiments: Recipient T cells (107/ 
ml), obtained before xenotransplantation, were cultured 
for 10 days with irradiated splenocytes (107/ml) from the 
xenograft donor. At the end of the incubation period, 
lymphocytes were harvested, washed, and plated at 5 × 
10e/well in 96-well plates. Triplicate cultures were stimu- 
lated with an equal number of irradiated lymphocytes 
from the specific allograft donor and from an additional 
11 unrelated baboons. After 2 days of incubation the 
cultures were labeled with 3H-TdR, then harvested 24 
hours later, and the amount of 3H-TdR incorporation was 
measured. 
Results 
Histopathology. The extent and severity of allo- 
graft rejection in the baboons was unrelated to the 
extent and severity of xenograft rejection. The allo- 
graft in recipient 1 was explanted at 44 days for 
reasons unrelated to graft function and the remain- 
ing allografts were explanted 8 weeks after trans- 
plantation. At the time of explantation, all four 
allografts were beating. Despite the individual vari- 
ability of prior histologic xenograft rejection, rang- 
ing from mild to severe, all four allografts had a 
similar degree of potentially reversible histologic 
rejection (low moderate) (Fig. 1). In all cases, 
allograft rejection was characterized by multifocal 
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Fig. 1. Light microscopic studies of the xenografts and allografts of recipients 2 and 4 at the time of 
explantation demonstrating a similar degree of potentially reversible allograft rejection despite variability 
of prior xenograft rejection (hematoxylin and eosin stain; original magnification x250). A, Xenograft of 
recipient 2with no evidence of rejection (grade 1A). B, Allograft of recipient 2with low moderate r jection 
(grade 3A) as evidenced by focal areas of cellular infiltrates with some myocyte damage. C, Xenograft of 
recipient 4 with severe rejection as evidenced by myocyte necrosis, mononuclear cell infiltrates, and 
intravascular thrombosis. D, Allograft of recipient 4 with low moderate rejection (grade 3A) as evidenced 
by focal areas of cellular infiltrates with some myocyte damage. 
Table I. Proliferative response of primed recipient baboon lymphocytes tostimulating cells of the specific 
allogra]:t donor and a panel of 11 unrelated baboons 
Stimulator cells-baboon pa el 
Baboon Cyno donor A B C D E F G H I J K L 
1 a . . . . . .  + + . . . .  
2 b + - + . . . . . . . . .  
3 c . . . . .  + . . . . .  + 
4 d . . . . .  + + . . . .  
Baboon L served as the a l lograf t  donor  to rec ip ient  1, baboon G was the donor  to rec ip ient  2, baboon I to rec ip ient  3, and baboon H to rec ip ient  4. 
D 
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Fig. 2. Immunopathology of a characteristic allograft (recipient 4) at the time of graft explantation (8
weeks). A, IgM: Tissue sections reveal focal reactivity at a trace level. B, IgG: Tissue sections reveal tr ce 
reactivity in the interstitial space. C, C3: Tissue sections reveal no significant reactivity. D, C4: Tissue 
sections reveal nosignificant reactivity. E, MAC: Focal reactivity is apparent in the interstitium. F, Fibrin: 
Focal fibrin thrombi are present in small vessels and in the interstitium. 
cellular infiltrates with some myocyte damage. Im- 
munofluorescence revealed no significant endothe- 
lial cell deposition of IgM, IgG, C3, C4, or mem- 
brane attack complex at any time points after 
allotransplantation (Fig. 2). 
tIumoral response. Before xenotransplantation, 
two of the four baboons (recipients 2 and 3) had 
preformed alloreactive antibodies against MHC 
class II-like antigens of six and seven baboons in the 
panel (n = 12), respectively. After xenotransplanta- 
tion, no additional alloreactive antibodies developed 
in either of these baboons. During the time interval 
from xenotransplantation to allotransplantation 
both recipients 1and 4 acquired new-onset alloreac- 
tive cytotoxic antibodies directed against he MHC 
class II-like antigens of six of the 12 members in the 
panel. These were primarily of IgG isotype. In 
baboon recipient 1, the subsequent allograft donor 
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was among the baboons against which alloreactive 
antibodies developed after xenotransplantation. 
However, this did not have any obvious bearing on 
the severity of histologic allograft rejection, inas- 
much as grade 3A rejection at explantation was 
found in this as well as all other allografts. 
After allotransplantation, new-onset alloreactive 
and xenoreactive antibodies developed simulta- 
neously in one baboon (recipient 2). So that we 
could establish whether this animal's serum con- 
tained two populations of antibodies, one reacting 
with xenogeneic and the other with allogeneic lym- 
phocytes, or whether there was a single population 
of antibodies reactive with both species, serum was 
preadsorbed on either xenogeneic or allogeneic 
lymphocytes and then tested for reactivity with 
either target cell type. Antibody reactivity against 
xenogeneic lymphocytes could be removed by 
preadsorption of serum on xenogeneic but not allo- 
geneic lymphocytes. Similarly, alloreactive antibod- 
ies were removed by preadsorption on allogeneic 
but not xenogeneic cells. These results indicate that 
in addition to the induction of specific alloantibod- 
ies, allotransplantation after xenotransplantation 
can reactivate B-cell clones with specificity for xe- 
nogeneic antigens. 
Cell-mediated proliferative and cytotoxic re- 
sponses. The T-cell lines propagated from the xe- 
nograft biopsy tissue demonstrated no proliferative 
responses when cultured with xenogeneic or alloge- 
neic irradiated peripheral blood mononuctear cells. 
The proliferative response of recipient lymphocytes 
primed in vitro by xenograft donor splenocytes to 
lymphocytes from the specific allograft donor and a 
panel (n = 12) of unrelated allograft donors was 
then determined (Table I). After priming with xe- 
nogeneic splenocytes, each baboon recipient dem- 
onstrated an accelerated proliferative response to 
two of 12 unrelated baboons in the panel. One of the 
four baboon recipients (recipient 4) had a prolifer- 
ative response to its subsequent allograft donor. 
Recipients 1 and 4 had a proliferative response to 
the same two baboons in the panel, raising the 
possibility that these recipients were responding to 
similar MHC class II-like structures. In the absence 
of priming, there was no proliferation of recipient 
lymphocytes to the unrelated baboons in the panel. 
To determine whether the T-cell lines infiltrating 
the xenograffs contained onor-specific cytotoxic T
lymphocytes, we performed cell-mediated lympho- 
cytotoxicity assays. In three of the four baboons, 
T-cell lines propagated from xenograft biopsies had 
I 00 -  
lib Cyno lymphocytes 
[ ]  Baboon lymphocytes 
80 ¸ 
=~ 60 ¸ 
. J  
~'~ 40 .  
20 
I 2 3 4 
Baboon 
Fig. 3. Cell-mediated lymphocytotoxicity of xenograft T- 
cell lines to xenogeneic and allogeneic target cells. 
specific cytotoxic activity to xenogeneic target cells 
(Fig. 3). In contrast, none of these lines had cyto- 
toxic activity directed against he subsequent allo- 
graft donor. 
Discussion 
This study demonstrates that a concordant pri- 
mate xenograft bridge does not induce an acceler- 
ated humoral or cell-mediated immune response 
that jeopardizes a subsequent allograft. Moreover, 
the degree of xenospecific immune reactivity, as 
determined by specific cytotoxicity of recipient T- 
cell lines derived from the xenograft, and extent of 
histologic xenograft rejection did not predict the 
extent or severity of subsequent allograft rejection. 
In two of the four recipients, xenotransplantation 
induced an alloreactive humoral response against 
the MHC class II-like antigens of more than 50% of 
members from a panel of 12 unrelated baboons. In 
all recipients, priming with xenogeneic splenocytes 
in vitro induced an accelerated proliferative T-cell 
response to allogeneic lymphocytes from 16% of this 
panel. However, the induction of allospecific anti- 
body and T-cell proliferative responses by xeno- 
transplantation did not appear to adversely influ- 
ence allograft function inasmuch as the histologic 
appearance of all allografts at explantation was 
similar, irrespective of whether alloreactive re- 
sponses, including those directed to the specific 
allograft donor, had been present before allotrans- 
plantation. 
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CD4 T lymphocytes play a major role in the 
initiation of both humoral and cell-mediated allo- 
reactive immunologic responses in clinical trans- 
plantation. These immunologic responses primarily 
develop as a consequence of CD4 T-cell allorecog- 
nition of foreign MHC class II antigens. In our 
model, baboon memory CD4 T cells reactive with 
xenogeneic MHC class II-like antigens are likely to 
have persisted even after xenograft explantation. 
Inasmuch as prior exposure of baboon CD4 T cells 
to xenogeneic targets induced accelerated humoral 
and T-cell proliferative responses against unrelated 
allogeneic targets, it is likely that the baboon mem- 
ory CD4 T cells recognized similar MHC class II 
structures present in the xenografts and in the 
allogeneic ells. Although allotransplantation in the 
setting of preformed onor-specific antibodies and 
T-cell proliferative responses did not adversely in- 
fluence outcome in this model, the presence of 
similar alloresponses after xenotransplantation in 
human beings could theoretically preclude the use 
of donors against which recipients have acquired 
humoral sensitization. It is important o note that 
the baboon recipients in this study received immu- 
nosuppression with a regimen containing azathio- 
prine. Current strategies to limit the development of
humoral immunity after xenotransplantation would 
include substitution of mycophenolic acid or other 
newer agents with more potent anti-B-cell activity. 
Whether limited proliferative responses to alloge- 
neic targets would also be induced in human beings 
by xenotransplantation, and whether these would 
have a significant impact on allograft survival, re- 
quires investigation. Although performance of a 
mixed lymphocyte reactivity test between a concor- 
dant xenograft recipient and any potential allograft 
donor appears indicated, time considerations would 
make it difficult to perform a 24- to 48-hour prolif- 
erative assay after a potential allograft donor has 
been identified. However, inasmuch as allorecogni- 
tion appears directed toward MHC class II antigens, 
one could perform prospectively primed mixed lym- 
phocyte reactions to cell panels of known human 
leukocyte antigen class II (DR/DQ) type and iden- 
tify which antigens elicit a proliferative response. 
Human leukocyte antigen class II typing could then 
be performed on potential donors to exclude those 
with the antigens known to elicit a proliferative 
response. 
This study demonstrated that concordant xe- 
nografts implanted in primates as a bridge to allo- 
transplantation did not induce humoral or cell- 
mediated immune responses that jeopardized 
subsequent allografts. However, our findings do 
suggest hat concordant xenotransplantation may 
induce cross-reactive allorecognition of MHC class 
II-like structures. While affirming the role of con- 
cordant xenografts as appropriate biologic bridges 
to human allotransplantation, the immune re- 
sponses resulting from the potential sensitization by 
a xenograft may affect the process of subsequent 
allograft donor selection. 
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